Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Descartes 30

Cell therapy (Stem-cell derived) · Acts on extracellular DNA · developed by Cartesian Therapeutics

Phase 1 Most advanced trial (none active)

RNAC Developer

1 Registered trials

What is Descartes 30?

Descartes 30 is a cell therapy consisting of mesenchymal stem cells engineered to secrete DNases. It is being studied in acute respiratory distress syndrome and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Stem-cell derived)
Targets: extracellular DNA
Mechanism: Acts on extracellular DNA
Therapy area: Infectious disease, Respiratory
Developer: Cartesian Therapeutics (RNAC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 4P8TSC4FR8

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04524962	Phase 1	Acute Respiratory Distress Syndrome	Terminated	RNAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Respiratory Distress SyndromeCovid19

More from Cartesian Therapeutics

Descartes-08 Phase 3 Descartes-11 Phase 2 Descartes-15 Phase 1 Descartes-25 Phase 1

Sources

ClinicalTrials.gov NCT04524962

Updated Oct 3, 2026. Something wrong or missing? Report it on the RNAC page.

Follow RNAC, the company behind Descartes 30

See RNAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNAC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z